SOUTH SAN FRANCISCO, Calif.-- Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through. South San Francisco, Calif.- based Theravance said Monday it will split into businesses named Royalty Management Co. and Theravance Biopharma.» Read More
March 2- Celgene Corp's experimental drug apremilast proved to be more effective than a dummy pill for psoriasis patients in a late-stage study, clearing the way for the company to file for U.S. regulatory approval in the second half of 2013..
NEW YORK, Feb 25- Michael Weitz was out of options. It typically has taken a decade and $1 billion to bring a new treatment to market.
CNBC's Jon Fortt speaks with Facebook founder & CEO Mark Zuckerberg and Apple Chairman Art Levinson about a new foundation to offer a $33 million prize for life science research. "We all think our society needs more heroes who are scientists, researchers and engineers," he says.
CHICAGO, Feb 1- After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year. "In my own personal view, I will consider this to be a landmark or a watershed," said Peggy Johnston, senior program officer at the Bill& Melinda Gates Foundation in Seattle.
NEW YORK, Jan 30- Sarepta Therapeutics Inc became the second company in as many days see its shares plunge as a result of a Twitter hoax on Wednesday after a user posed as an influential short-seller and alleged improprieties at the biopharmaceutical company.
*4th- qtr profit 89 cents/ share vs 82 cents a year ago. Jan 24- Medical device and bioscience company Baxter International Inc reported higher quarterly earnings on Thursday and forecast sales growth of 10 percent for 2013..
Japan has one of the world’s highest suicide rates. But last year the number of suicides fell below 30,000 for the first time in 15 years, thanks in part to community efforts. The CSM reports.
*Novartis seeks to sell Bexsero as soon as possible. ZURICH, Jan 22- Novartis won European approval for the first vaccine against meningitis B and is seeking to persuade cash-strapped governments to add it to routine vaccination programs to ensure the drug's commercial success.
*Sanofi runs out of most vaccine dosages. Sanofi SA, the largest flu vaccine provider in the United States, said on Thursday it had sold out of four of the six different dosages of Fluzone seasonal flu vaccine due to unanticipated demand.
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
MILAN, Jan 3- Italian biopharmaceutical company Philogen has signed a worldwide licence agreement with drug firm Pfizer for the development of Dekavil, an experimental treatment for autoimmune diseases. Under the deal, Pfizer will retain exclusive rights to market any products developed during the collaboration, Philogen said in a statement on Thursday.
The National Geographic Channel is preparing to beam tweets into space, in response to the "Wow! signal," a transmission received from space.
BGI, based in China, is the world’s largest genomics research institute, with 167 DNA sequencers producing the equivalent of 2,000 human genomes a day, the New York Times reports.
Scientists have discovered neural pathways that seem to correlate with the kinds of people who deal well with financial risk, but even the very definition of risk gets pulled apart by experts.
DSM Chairman and CEO Feike Sijbesma told CNBC he expects the Dutch chemicals firm to perform well in the second half of the year following strong second quarter results which saw a boost in net profit, while revenue fell just shy of the Reuters average forecast.